Dermapharm Holding SE
DMPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,180,766 | $1,150,741 | $1,024,776 | $942,912 |
| % Growth | 2.6% | 12.3% | 8.7% | – |
| Cost of Goods Sold | $413,696 | $446,597 | $363,943 | $322,218 |
| Gross Profit | $767,070 | $704,144 | $660,833 | $620,694 |
| % Margin | 65% | 61.2% | 64.5% | 65.8% |
| R&D Expenses | $11,535 | $19,890 | $13,178 | $14,174 |
| G&A Expenses | $13,563 | $20,240 | $16,103 | $13,069 |
| SG&A Expenses | $88,376 | $95,283 | $66,748 | $65,882 |
| Sales & Mktg Exp. | $74,813 | $75,043 | $50,645 | $52,813 |
| Other Operating Expenses | $450,226 | $230,346 | $3,110 | $7,813 |
| Operating Expenses | $550,137 | $521,250 | $418,784 | $333,651 |
| Operating Income | $216,933 | $182,894 | $243,687 | $298,469 |
| % Margin | 18.4% | 15.9% | 23.8% | 31.7% |
| Other Income/Exp. Net | -$44,928 | -$76,897 | -$27,390 | -$5,492 |
| Pre-Tax Income | $172,005 | $105,997 | $216,297 | $292,977 |
| Tax Expense | $60,268 | $45,462 | $83,680 | $84,073 |
| Net Income | $113,787 | $62,368 | $134,236 | $209,583 |
| % Margin | 9.6% | 5.4% | 13.1% | 22.2% |
| EPS | 2.11 | 1.16 | 2.49 | 3.89 |
| % Growth | 81.9% | -53.4% | -36% | – |
| EPS Diluted | 2.11 | 1.16 | 2.49 | 3.89 |
| Weighted Avg Shares Out | 53,963 | 53,840 | 53,840 | 53,840 |
| Weighted Avg Shares Out Dil | 53,963 | 53,840 | 53,840 | 53,840 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13,988 | $2,494 | $348 | $4,022 |
| Interest Expense | $58,408 | $54,968 | $14,840 | $8,837 |
| Depreciation & Amortization | $90,495 | $101,772 | $94,909 | $55,159 |
| EBITDA | $320,908 | $262,737 | $323,544 | $356,973 |
| % Margin | 27.2% | 22.8% | 31.6% | 37.9% |